03:55 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Filaments line up as MS biomarker

Neurofilament assays appear on track to become the biomarker of choice for a wide range of neurodegeneration studies, given their tight correlation with axon damage and detectability in blood. If prospective trials can reinforce the...
17:38 , Nov 16, 2018 |  BC Week In Review  |  Company News

bioMérieux grows China footprint with majority stake in Hybiome

Increasing its presence in China and the immunoassay market, France’s bioMérieux S.A. (Euronext:BIM) acquired a majority stake in fellow diagnostics company Suzhou Hybiome Biomedical Engineering Co. Ltd. (Suzhou, China). bioMérieux said it acquired 54% of...
20:37 , Nov 12, 2018 |  BC Extra  |  Company News

bioMérieux grows China footprint with majority stake in Hybiome

Increasing its presence in China and the immunoassay market, France’s bioMérieux S.A. (Euronext:BIM) acquired a majority stake in fellow diagnostics company Suzhou Hybiome Biomedical Engineering Co. Ltd. (Suzhou, China). bioMérieux said it acquired 54% of...
22:18 , Aug 1, 2018 |  BC Extra  |  Company News

Management tracks: Hologic, Tricidia

Hologic Inc. (NASDAQ:HOLX) said Bob McMahon has departed as CFO to become CFO at Agilent Technologies Inc. (NYSE:A). The diagnostics company promoted Chief Accounting Officer Karleen Oberton to CFO. Metabolic acidosis play Tricida Inc. (NASDAQ:TCDA)...
19:38 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA approves Banyan's brain trauma blood test

FDA approved the Banyan Brain Trauma Indicator (BTI) from Banyan Biomarkers Inc. (Alachua, Fla.) as an in vitro diagnostic blood test to aid in the evaluation of adults with suspected mild traumatic brain injury (TBI)....
02:09 , Jan 22, 2016 |  BC Extra  |  Financial News

bioMerieux spinout bioTheranostics raises $32M

bioTheranostics Inc. raised $32 million in an equity round and said it will spin out from parent company bioMerieux S.A. (Euronext:BIM). MVM Life Science Partners led the round, in which Canepa Advanced Healthcare Fund and...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

FilmArray Meningitis/Encephalitis Panel regulatory update

FDA granted 510(k) clearance to bioMerieux’s FilmArray Meningitis/Encephalitis Panel for simultaneous detection of multiple pathogens that can cause CNS infections. The panel is an in vitro multiplex PCR platform that detects 14 bacterial, viral and...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

bioMerieux, Celsee deal

bioMerieux’s bioTheranostics Inc. subsidiary partnered with Celsee to investigate the technical feasibility of using bioTheranostics’ biomarkers for molecular characterization of circulating tumor cells (CTCs) enriched and captured with Celsee’s Jetta CTC platform in proof-of-concept (POC)...
07:00 , Jun 11, 2015 |  BC Innovations  |  Targets & Mechanisms

GeNeuro goes retro

GeNeuro S.A. put human endogenous retroviruses on the map as drug targets for multiple sclerosis, but new data point to a pathological role for the viruses in a much broader spectrum of diseases. Now GeNeuro...
07:00 , Apr 23, 2015 |  BC Innovations  |  Translation in Brief

Funding faster diagnostics

Just two weeks after the White House released its National Action Plan for Combating Antibiotic Resistant Bacteria on March 27, NIH's National Institute of Allergy and Infectious Diseases (NIAID) announced it is awarding more than...